- Home
- RARE vs BATRK Comparison
RARE vs BATRK Comparison
Compare RARE & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- BATRK
- Stock Information
- Founded
- RARE 2010
- BATRK 1991
- Country
- RARE United States
- BATRK United States
- Employees
- RARE N/A
- BATRK N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- BATRK Broadcasting
- Sector
- RARE Health Care
- BATRK Industrials
- Exchange
- RARE Nasdaq
- BATRK Nasdaq
- Market Cap
- RARE 3.5B
- BATRK 2.9B
- IPO Year
- RARE 2014
- BATRK N/A
- Fundamental
- Price
- RARE $39.91
- BATRK $46.65
- Analyst Decision
- RARE Strong Buy
- BATRK Strong Buy
- Analyst Count
- RARE 15
- BATRK 3
- Target Price
- RARE $90.53
- BATRK $58.00
- AVG Volume (30 Days)
- RARE 1.1M
- BATRK 397.0K
- Earning Date
- RARE 07-31-2025
- BATRK 08-07-2025
- Dividend Yield
- RARE N/A
- BATRK N/A
- EPS Growth
- RARE N/A
- BATRK N/A
- EPS
- RARE N/A
- BATRK N/A
- Revenue
- RARE $590,689,000.00
- BATRK $672,879,000.00
- Revenue This Year
- RARE $18.94
- BATRK $8.81
- Revenue Next Year
- RARE $28.93
- BATRK $5.01
- P/E Ratio
- RARE N/A
- BATRK N/A
- Revenue Growth
- RARE 33.46
- BATRK 4.04
- 52 Week Low
- RARE $29.59
- BATRK $35.46
- 52 Week High
- RARE $60.37
- BATRK $47.03
- Technical
- Relative Strength Index (RSI)
- RARE 65.02
- BATRK 70.46
- Support Level
- RARE $35.51
- BATRK $45.25
- Resistance Level
- RARE $38.19
- BATRK $47.03
- Average True Range (ATR)
- RARE 1.58
- BATRK 0.99
- MACD
- RARE 0.20
- BATRK 0.09
- Stochastic Oscillator
- RARE 98.43
- BATRK 91.80
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.